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http://Is it safe to use pharmacological agents for induction of labor?The risk of perinatal morbidity or mortality for pregnant
women with oligohydramnios is higher than that for pregnant
women with normal amniotic fluid index, and is often sec-
ondary to various kinds of medical or obstetric disorders such
as preeclampsia and systemic lupus erythematosus.1e3 When
continuation of the pregnancy might jeopardize patient health
and possibly result in subsequent life-threatening catastrophic
circumstances for pregnant women or their babies, delivery
may be a better choice compared to continuing the pregnancy.4
Therefore, labor induction is often used in such critical sit-
uations, a common obstetric intervention that artificially ini-
tiates the process of effacement of the cervix, dilatation of the
cervix, and uterine contractions as well as routinely results in
successful vaginal delivery. However, induction of labor itself,
especially applied at an inappropriate time, may increase the
risk of perinatal morbidity and/or cesarean delivery, which is
already common in this high-risk group.5 Additionally,
cesarean delivery occurs much more frequently in women with
an unfavorable cervix condition who have scheduled labor
induction.4
Induction of labor starting with cervical ripening through
the Foley catheter method has been a generally accepted
technique and believed to be the safest method to manage
pregnant women with an unfavorable cervix because it avoids
exogenous uterine stimulants and relies on the local and
endogenous prostaglandin release.6 This mechanical method
utilizes a simple Foley catheter bulb that is passed through the
cervix and inflated in the potential space between the amniotic
sac and the uterus.6 In recent decades, following the intro-
duction of pharmacological agents such as prostaglandin E1
(misoprostol) or E2 analogues (dinoprostone),6e9 these drugs
have given the medical community and patients promising and
exciting drug treatments. Typically, these drugs are widely
used after a promotional budget becomes continuous. In
addition, the results of a multicenter randomized controlled
noninferiority trial that compared oral misoprostol versus a
Foley catheter for induction of labor at term (PROBAAT-II)
supported a similar safety and effectiveness between the two
methods in the induction of labor for women with an unfav-
orable cervix at term.4 Although the PROBAAT-II study
favored the benefits of misoprostol, such as low price, ease of
storage, extended shelf life at room temperature, andx.doi.org/10.1016/j.jcma.2016.07.001
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countries where there are reservations about induction owing
to a high prevalence of infection, and the risk of vertical
transmission is present,4 there are still many uncertainties that
should be clarified. For example, the oral administration of
misoprostol to induce labor has a higher risk of postpartum
hemorrhage, elevated frequency of asphyxia, and a 3.8 times
greater incidence of spontaneous rupture of the membrane
compared with the Foley catheter method in other studies.4,6
One systematic review and network meta-analysis was
conducted to compare the use of Foley catheters, misoprostol,
and dinoprostone for cervical ripening in labor induction; the
results showed that no method of labor induction revealed
overall superiority when all outcomes (rates of failure to
achieve vaginal delivery within 24 hours, incidence of uterine
hyperstimulation with fetal heart rate changes, and rates of
cesarean delivery) were considered, because the following
results were found: (1) vaginal misoprostol is most likely to
achieve vaginal delivery within 24 hours; (2) vaginal miso-
prostol is most likely to be the worst treatment for increased
uterine hyperstimulation; and (3) Foley catheter is least likely
to cause hyperstimulation, but is the worst treatment in ach-
ieving vaginal delivery within 24 hours.10 However, it is
interesting that the authors who conducted this systematic
review and meta-analysis still suggested that oral misoprostol
for the induction of labor is safer than vaginal misoprostol and
has the lowest rate of cesarean delivery.10 In fact, misoprostol
has been recommended to be used for induction of labor by the
World Health Organization (WHO) and the American College
of Obstetricians and Gynecologists, but misoprostol remains
unapproved for induction or labor.4 Unlike misoprostol,
dinoprostone is generally more acceptable and has been
widely used for cervical ripening. Therefore, it is not sur-
prising that Kansu-Celik and colleagues9 used dinoprostone as
an agent for induction of labor in their study published in this
issue of the Journal of Chinese Medical Association.
The study by Kansu-Celik and colleagues9 investigated 40
pregnant women, with a singleton live cephalic presentation
between 37 and 42 gestational weeks, intact amniotic mem-
brane, oligohydramnios, reassuring fetal heart rate, and
unfavorable uterine cervix (Bishop score  5) without other
remarkable obstetric or surgical history. These women visitedvier Taiwan LLC. This is an open access article under the CC BY-NC-ND li-
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cation Hospital between April 2009 and August 2009. Kansu-
Celik and colleagues9 attempted to evaluate the efficacy and
safety of dinoprostone for cervical ripening and labor induc-
tion in pregnant women with term oligohydramnios and
unfavorable uterine cervix.9 In the same study, 64 pregnant
women with normal amniotic fluid index were included as
controls.9 The results showed that there was no statistically
significant difference in induction time to delivery between the
two groups, and the perinatal and neonatal outcomes were also
similar between the two groups.9 Therefore, Kansu-Celik and
colleagues9 concluded that dinoprostone is a safe alternative
for induction of labor in women with oligohydramnios with
term pregnancies. This study reconfirmed the safety of dino-
prostone; however, fetal distress manifested more frequently in
the oligohydramnios group than in the normal control group
(20% vs. 4.7%), contributing to a higher cesarean delivery rate
in the oligohydramnios group, although uterine hyper-
stimulation occurred in 10% (4/40) of pregnant women with
oligohydramnios. In fact, neonatal intensive care unit admis-
sion within 24 hours after delivery was also higher in the
oligohydramnios group (7.5% vs. 3.1%). Therefore, the use of
vaginal dinoprostone for induction of labor in women with
oligohydramnios at term might be applied over-
enthusiastically. Kansu-Celik and colleagues9 might overlook
the potential risk if dinoprostone is used as an agent for labor
induction for pregnant women with oligohydramnios at term.
We would encourage researchers to replicate this study in a
future investigation9 to reevaluate the safety and effectiveness
of either prostaglandin E1 or E2 for cervical ripening and
labor induction in pregnant women who need induction of
labor, regardless of whatever indication is noted.Conflicts of interest
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